ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 2900 • 2018 ACR/ARHP Annual Meeting

    Impaired TCR Signaling Paves the Way for Cytokine Hyper-Responsiveness in Arthritogenic T Cells

    Judith Ashouri1, Lih-Yun Hsu1, Dmitry Rychkov2, Marina Sirota2, Lisa Lattanza3, Eric Hansen3, Julie Zikherman1 and Arthur Weiss1, 1Rosalind Russell and Ephraim P. Engleman Rheumatology Research Center, Department of Medicine, Division of Rheumatology, University of California, San Francisco, San Francisco, CA, 2Pediatrics, Institute for Computational Health Sciences, University of California, San Francisco, San Francisco, CA, 3Orthopedic Surgery, University of California, San Francisco, San Francisco, CA

    Background/Purpose: The inability to identify relevant arthritogenic CD4 T cells in patients and in murine disease models has limited our understanding of disease initiating events…
  • Abstract Number: 827 • 2018 ACR/ARHP Annual Meeting

    Rituximab Therapy for Systemic Rheumatoid Vasculitis: Indications, Outcomes and Adverse Events

    Caitrin Coffey1, Michael Richter1, Cynthia S. Crowson2, Matthew J. Koster3, Kenneth J. Warrington4 and Ashima Makol3, 1Internal Medicine, Mayo Clinic, Rochester, MN, 2Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, 3Rheumatology, Mayo Clinic, Rochester, MN, 4Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN

    Background/Purpose: Rheumatoid vasculitis (RV) is a rare systemic inflammatory process affecting small to medium sized blood vessels in patients with rheumatoid arthritis (RA). RV confers…
  • Abstract Number: 963 • 2018 ACR/ARHP Annual Meeting

    Long-Term Safety of Tofacitinib up to 9.5 Years: A Comprehensive Integrated Analysis of the RA Clinical Development Program

    Stanley Cohen1, Yoshiya Tanaka2, Xavier Mariette3, Jeffrey R. Curtis4, Eun Bong Lee5, Peter Nash6, Kevin Winthrop7, Christina Charles-Schoeman8, Lisy Wang9, Connie Chen10, Kenneth Kwok10, Pinaki Biswas10, Andrea Shapiro11, Ann Madsen10 and Jürgen Wollenhaupt12, 1Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, 2University of Occupational and Environmental Health, Kitakyushu, Japan, 3Paris-Sud University, Le Kremlin Bicêtre, France, 4University of Alabama at Birmingham, Birmingham, AL, 5Seoul National University, Seoul, Korea, Republic of (South), 6University of Queensland, Brisbane, Australia, 7Oregon Health and Science University, Portland, OR, 8University of California, Los Angeles, CA, 9Pfizer Inc, Groton, CT, 10Pfizer Inc, New York, NY, 11Pfizer Inc, Peapack, NJ, 12Schön-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Here, we report the largest integrated safety analysis of tofacitinib to date…
  • Abstract Number: 987 • 2018 ACR/ARHP Annual Meeting

    CCL11 Is Involved in Cell Migration in Rheumatoid Arthritis

    Kuninobu Wakabayashi, Takeo Isozaki, Shinichiro Nishimi and Tsuyoshi Kasama, Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan

    Background/Purpose: Chemokine C-C motif ligand 11 (CCL11) also known as eotaxin-1 is produced by a variety of cell types. By interacting with C-C chemokine receptor…
  • Abstract Number: 43 • 2018 ACR/ARHP Annual Meeting

    Novel Anti-Malarial Drug Derivative Inhibited Anti-Citrullinated Protein/Peptide Antibodies and Rheumatoid Factors Production in Dnaseii/Ifnr Double Knock out Mice

    Jie An1, Bhanupriya Madarampalli2, Xizhang Sun2, Lena Tanaka3, Erika H. Noss2, Joshua Woodward4, Tomikazu Sasaki5 and Keith B. Elkon6, 1Division of Rheumatology, University of Washington, Seattle, WA, 2Rheumatology, University of Washington, Seattle, WA, 3Medicine/Rheumatology, University of Washington, Seattle, WA, 4Department of Microbiology, University of Washington, Seattle, WA, 5Department of Chemistry, University of Washington, Seattle, WA, 6University of Washington, Seattle, WA

    Background/Purpose: Rheumatoid Arthritis (RA) is a highly prevalent autoimmune disease affecting ~1% of the world population and can lead to permanent joint damage and severe…
  • Abstract Number: 1073 • 2018 ACR/ARHP Annual Meeting

    Connective Tissue Growth Factor Associates with Angiogenesis through Notch-1 Activation in Rheumatoid Arthritis

    Kazuhisa Nozawa1, Takuya Hirai2, Hiroshi Tsushima2, Ken Yamaji3, Naoto Tamura3 and Iwao Sekigawa4, 12-1-1 Hongo Bunkyo-ku, Juntendo University, Tokyo, Japan, 2Rheumatology, Juntendo University Faculty of Medicine, Tokyo, Japan, 3Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, 4Institute for Environment and Gender Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan

    Background/Purpose: Aberrant angiogenesis has been considered as one of important factors for pathogenesis of rheumatoid arthritis (RA). Several angiogenetic mediators are reported to be massively…
  • Abstract Number: 47 • 2018 ACR/ARHP Annual Meeting

    Analysis of the Role of RORγt+Foxp3+ T Regulatory 17 (Tr17) Cells in Murine Autoimmune Arthritis Model

    Kotona Furuyama1, Yuya Kondo1, Masaru Shimizu2, Iizuka Akira1, Masahiro Yokosawa1, Seiji Segawa1, Hiroto Tsuboi1, Isao Matsumoto1 and Takayuki Sumida1, 1Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, 2Internal Medicine, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan

    Background/Purpose: RORγt+Foxp3+ regulatory T (Treg) cells, designated as Tr17 is one of the new subset of Treg cells, having the potential to regulate the development…
  • Abstract Number: 1076 • 2018 ACR/ARHP Annual Meeting

    Phospholipase C-eta2, As a C2 Domain-Containing Protein, Regulate Aggressiveness of Fibroblast‐like Synoviocytes and Ameliorate Arthritis in Experimental Animal Models of Rheumatoid Arthritis

    Mingyo Kim, Hyun Min Jeon, Hae Sook Noh, Sang Mi Yi and Sang-Il Lee, Department of Internal Medicine and Institute of Health Science, Gyeongsang National University School of Medicine, Jinju, Korea, Republic of (South)

    Background/Purpose: The C2 domain is a Ca2+-dependent membrane-targeting motif found in many cellular proteins involved in signal transduction or inflammatory pathway. However, the effects of…
  • Abstract Number: 50 • 2018 ACR/ARHP Annual Meeting

    Intra-Articularly Delivering Lentivirus-Based CRISPR Interference Targeting Long Non-Coding RNA H19 in Synovial Fibroblasts Ameliorates Experimental Arthritis

    Chrong-Reen Wang1, Shih-Yao Chen2, Yu-Ting Lo3, Yu-Chi Chou4, Ming-Fei Liu1, Chao-Liang Wu5 and Ai-Li Shiau3, 1Internal Medicine, National Cheng Kung University Hospital and Medical College, Tainan, Taiwan, 2Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan, 3Microbiology and Immunology, National Cheng Kung University Medical College, Tainan, Taiwan, 4Core Facility for Manipulation of Gene Function, Academia Sinica, Taipei, Taiwan, 5Biochemistry and Molecular Biology, National Cheng Kung University Medical College, Tainan, Taiwan

    Background/Purpose: Aberrantly higher expression of long non-coding RNAs (lncRNAs) in synovial fibroblasts (SFs) plays pathogenic roles in rheumatoid joint. Studying the effects on knocking down…
  • Abstract Number: 1201 • 2018 ACR/ARHP Annual Meeting

    Finger Extensor Tendon Involvement Is Frequent in Early Rheumatoid Arthritis

    Mihaela Maruseac1, Patrick Durez2,3, Adrien Nzeusseu Toukap4 and Maria Stoenoiu5, 1Rheumatology, Cliniques Universitaires Saint-Luc, Brussels, Belgium, 2Pôle de Maladies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, 3Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium, 4Department of Rheumatology, Rheumatology - Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, 5Rheumatology, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium

    Background/Purpose: Finger extensor involvement (FET) at ultrasound examination (US) was previously described in patients suffering from early psoriatic arthritis. Contradictory results were published in patients…
  • Abstract Number: 53 • 2018 ACR/ARHP Annual Meeting

    Cyclin-Dependent Kinase 4/6 Inhibitor: A Promising Development Candidate Targeting Synovial Hypertrophy for Rheumatoid Arthritis Treatment

    Shunsuke Tsujimoto, Kyohei Horie, Toshiya Mashiko, Johji Nomura and Tsunefumi Kobayashi, Teijin Institute for Bio-medical Research, TEIJIN PHARMA LIMITED, Tokyo, Japan

    Background/Purpose: The pathogenesis of rheumatoid arthritis (RA) is characterized by the infiltration of immune cells into the synovial tissues and the hypertrophy of synovial fibroblasts,…
  • Abstract Number: 1519 • 2018 ACR/ARHP Annual Meeting

    Patient Characteristics Associated with Discontinuation of Tofacitinib for the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 9.5 Years

    Jeffrey R. Curtis1, Jürgen Wollenhaupt2, Katerina Chatzidionysiou3, Sander W. Tas4, Lisy Wang5, Harry Shi6, María Montoro7, Petra Neregård8, Palle Dahl9 and Vassilis Tsekouras10, 1University of Alabama at Birmingham, Birmingham, AL, 2Schön Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, 3Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 4Amsterdam Rheumatology and Immunology Center, Academic Medical Center, Amsterdam, Netherlands, 5Pfizer Inc, Groton, CT, 6Pfizer Inc, Collegeville, PA, 7Pfizer Inc, Madrid, Spain, 8Pfizer Inc, Stochholm, Sweden, 9Pfizer Inc, Ballerup, Denmark, 10Pfizer Inc, Athens, Greece

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. We explored characteristics of patients (pts) who discontinued (d/c) open-label, long-term extension…
  • Abstract Number: 55 • 2018 ACR/ARHP Annual Meeting

    Adipose Derived Stem Cell Suppressed Synovial Inflammation and Repaired Cartilage Destruction in Rheumatoid Arthritis Model Mice

    Tadashi Okano1, Kentaro Inui2, Hideki Ueyama3, Kumi Orita3, Tatsuya Koike4 and Hiroaki Nakamura2, 1Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, 2Orthopaedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, 3Osaka City University Graduate School of Medicine, Osaka, Japan, 4Center for Senile Degenerative Disorders, Osaka City University Graduate School of Medicine, Osaka, Japan

    Background/Purpose: Adipose derived stem cell (ADSC) is one of the stem cells produced by adipose tissue which can be collected easily and in large quantities.…
  • Abstract Number: 1526 • 2018 ACR/ARHP Annual Meeting

    Baseline Characteristics and Outcomes in Patients with Anemia in Clinical Studies of Tofacitinib

    Burkhard Moeller1, Axel Finckh2, Jose Maria Alvaro-Gracia3, Godehard Scholz1, Daniel Aletaha4, Francesca Biondo5, Sander Strengholt6, Jose L Rivas7, Carol A Connell8 and Harry Shi9, 1Inselspital-University Hospital, Bern, Switzerland, 2University Hospital of Geneva, Geneva, Switzerland, 3Hospital Universitario de La Princesa, Madrid, Spain, 4Medical University of Vienna, Vienna, Austria, 5Pfizer Inc, Rome, Italy, 6Pfizer Inc, Capelle aan den IJssel, Netherlands, 7Pfizer SLU, Madrid, Spain, 8Pfizer Inc, Groton, CT, 9Pfizer Inc, Collegeville, PA

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The purpose of this study is to describe the profile of patients…
  • Abstract Number: 59 • 2018 ACR/ARHP Annual Meeting

    Elucidating the Expression and Role of Heparan Sulfate Proteoglycan Editing Sulfatases in Human Rheumatoid Arthritis Synovium and a Rat Adjuvant-Induced Arthritis Model

    Ruby J. Siegel1, Solomon A. Agere1, Anil K. Singh1 and Salahuddin Ahmed2,3, 1Washington State University, Department of Pharmaceutical Sciences, College of Pharmacy, Spokane, WA, 2Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, 3Division of Rheumatology, University of Washington, Division of Rheumatology, School of Medicine, Seattle, WA

    Background/Purpose: Syndecans are cell-surface heparan sulfate proteoglycans (HSPGs) that modulate the receptor/ligand binding of chemokines, cytokines, and growth factors in order to facilitate cellular signaling.…
  • « Previous Page
  • 1
  • …
  • 200
  • 201
  • 202
  • 203
  • 204
  • …
  • 219
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology